Michael Wasserman, Ph.D., is a Partner and COO of Elevage Medical Technologies. Michael has over 30 years of experience in healthcare as a scientist, entrepreneur, executive, and investor. Prior to Elevage, Michael served as Managing Partner of Maverix Private Equity. Michael spent 17 years at H.I.G. Capital, a diversified private equity firm with over $60 billion in assets. As a Managing Director of H.I.G.’s BioHealth platform, Michael sourced, executed, and managed a diverse investment portfolio of healthcare business across stages, sectors and geographies. Michael worked closely with management teams and portfolio companies in key areas such as R&D, product development, market access, commercial and corporate strategy, equity and debt financing and achieving liquidity through M&A or IPO.

Michael has served on the boards of numerous growth stage business including HyperBranch Medical Technologies (Stryker), NeuWave Medical (Johnson & Johnson), VertiFlex (Boston Scientific), amongst others. Michael has also founded, held prominent operating roles, and sold several private healthcare businesses. Earlier in his career, Michael worked directly for, or as a consultant to, emerging technology businesses, and in the corporate finance, pharmaceutical and clinical research industries.

Michael is a member of the Board of Trustees for the Holland Bloorview Kids Rehabilitation Hospital. He is also on the Board of Toronto Innovation Acceleration Partners (TIAP), where he chairs the Investment Committee; the Board of ORT Canad; the Faculty of Science Advisory Board at McGill University; and is a Member of The Board of Trustees Research Committee at The Center for Addiction and Mental Health.

Michael received his B.Sc. from McGill University and his Ph.D. in Pharmacology and Neuroscience from the University of Toronto.